Syncona’s pre-clinical portfolio companies are developing their pipelines, proprietary platforms and progressing towards entering clinical trials.
Syncona’s pre-clinical portfolio comprises companies with a broad range of focuses including: repairing inflammatory organ damage, chronic renal diseases, melanoma, multiple myeloma, heart attacks and protein homeostasis using a variety of modalities, including cell therapy, gene therapy and small molecules.
Key facts
Unless stated all financials at 31 March 2024
£202m
Value of pre-clinical portfolio
8
No. of companies
16
Portfolio company Board seats
Our pre-clinical portfolio companies
The pre-clinical portfolio pipeline
Best ideas
Pre-clinical
Clinical
Late Clinical
BLA
